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Abstract: We aimed to assess the effects of the antioxidant-rich Mediterranean diet (MedDiet) on
white blood cell count. Our study population included participants in the PREvención con DIeta
MEDiterránea study (average age 67 years old, 58% women, high cardiovascular risk). We assessed
whether a MedDiet intervention enriched in extra-virgin olive oil or nuts, versus a low-fat control
diet, modified the incidence of leukocytosis (>11 × 109 leukocytes/L), mild leukopenia (<4.5 × 109
leukocytes/L), or severe leukopenia (<3.5 × 109 leukocytes/L) in individuals without the condition
at baseline (n = 3190, n = 2925, and n = 3190, respectively). We also examined whether MedDiet
modified the association between leukocyte count alterations and all-cause mortality. Both MedDiet
interventions were associated with a lower risk of developing leukopenia (incidence rates: 5.06%
in control diet, 3.29% in MedDiet groups combined; hazard ratio [95% confidence interval]: 0.54
[0.36–0.80]) and severe leukopenia (incidence rates: 1.26% in control diet, 0.46% in MedDiet groups
combined; hazard ratio: 0.25 [0.10–0.60]). High cumulative adherence to a MedDiet was linked to
lower risk of leukocytosis (incidence rates: 2.08% in quartile 1, 0.65% in quartile 4; HRQ4-Q1: 0.29
[0.085–0.99]) and attenuated the association between leukopenia and all-cause mortality (P-interaction
= 0.032). In brief, MedDiet decreased the incidence of white blood cell count-related alterations in
high cardiovascular risk individuals.
Keywords: white blood cell count; Mediterranean diet; leukopenia; leukocytosis; randomized
controlled trial; prevention
1. Introduction
There is growing evidence that diet can modulate the response of the immune sys-
tem [1,2]. Experimental and clinical research in nutritional immunology has uncovered
several food components, such as dietary antioxidants (vitamin E, some phenolic com-
pounds), omega-3 polyunsaturated fatty acids, folates, vitamin A, zinc, and probiotics as
modifiable factors capable of impacting immune function [3–8]. However, immunomodula-
tory effects of some of these nutrients are yet to be proven beyond low-grade inflammation
(particularly in the case of vitamin E and phenolic antioxidants) [3,4,9,10]. Combining
these functionally diverse bioactive compounds in a healthy dietary pattern such as the
Mediterranean diet (MedDiet) may be a sound strategy to promote the overall function of
the immune system. In observational studies, adherence to the MedDiet has been consis-
tently associated with lower rates of cardiovascular disease [11], cancer [12], and all-cause
mortality [13]. There is also first-level evidence from the large-scale randomized clinical
trial PREDIMED (PREvención con DIeta MEDiterránea) on the efficacy of the MedDiet to
reduce incident cardiovascular disease [14], type 2 diabetes [15], and certain types of can-
cer [16] in older individuals at high cardiovascular risk. Adherence to a MedDiet has also
been associated with improvements in other immune-related responses such as cytokine
patterns [17,18], gut-derived immunity [19], and thrombosis [20,21]. A better functioning
of the immune system could be a mediator of these beneficial effects [22–25]. However, no
intervention study has assessed the effects of MedDiet on other immune-related responses
such as white blood cell (WBC) count. High and low WBC count have both been associated
with increased mortality [26–29] and are related to inadequate responses of the immune
system. On the one hand, high counts are intimately linked to chronic low-grade inflam-
mation [30] and the incidence of inflammation-related disease in the general population
and in individuals at high cardiovascular risk [31]. On the other hand, low WBC levels are
associated with nutritional deficiencies, chronic use of certain medications, and different
states of immune dysfunction such as autoimmune diseases, cancers of the immune system,
infections, and diseases of bone marrow, spleen, and blood [32,33]. WBC counts have been
shown to be potentially modulated by changes in the nutritional status in cross-sectional
or short-term studies [32,33]. Thus, an improvement in WBC counts and their related
conditions after following a MedDiet is plausible.
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Our primary aim was to assess the association of MedDiet with WBC count in middle-
aged and older individuals at high cardiovascular risk participating in the PREDIMED
study. Our secondary aim was to determine whether following a MedDiet modulated the
association between WBC count alterations and all-cause mortality.
2. Materials and Methods
2.1. Study Population
The study population were participants in the PREDIMED trial. It was a multicenter,
randomized, controlled trial conducted in Spain assessing the effects of the MedDiet
intervention on the primary prevention of cardiovascular outcomes in individuals at high
cardiovascular risk. Particularly, three intervention arms were compared: (1) a MedDiet
enriched with extra-virgin olive oil (MedDiet–EVOO), (2) a MedDiet enriched with mixed
nuts (MedDiet–Nuts), and (3) a low-fat control diet. Eligible participants were men (aged 55–
80 years) and women (aged 60–80 years) with no previous history of severe cardiovascular
disease at baseline, but presenting type 2 diabetes or three or more of the following risk
factors: smoking, hypertension, low-density lipoprotein cholesterol ≥160 mg/dL, high-
density lipoprotein cholesterol ≤40 mg/dL, overweight/obesity, and family history of
premature coronary heart disease [14,34]. Enrollment began on 25 June 2003, and the last
participant was recruited on 30 June 2009. The PREDIMED study was registered under the
International Standard Randomized Controlled Trial Number ISRCTN35739639. The study
protocol complied with the Declaration of Helsinki and was approved by the institutional
review boards of all recruiting centers. An institutional ethics committee (CEIC-PSMAR)
approved the particular protocol of this sub-project (code: 2018/8180/I, date: 4 December
2018). The study protocol, recruiting methods, and data collection processes have been
described elsewhere [14,34]. All volunteers provided written informed consent before
joining the trial.
The aim of this sub-study is to investigate the effects of MedDiet on WBC count,
which was not a predetermined endpoint in the PREDIMED study protocol. Of the 4381
participants recruited in the PREDIMED centers where complete blood count was collected
in yearly visits, we excluded 34 participants without baseline data on MedDiet adherence
or ethanol intake. To exclusively ascertain the effect of the dietary intervention on WBC
levels, we excluded individuals with any potential condition linked to WBC count alter-
ations [32,33], such as: (1) users of medications associated with alterations in WBC count
at any point of the study (90 users of oral corticosteroids and 23 users of psychoactive
drugs linked to WBC count alterations, such as bupropion, clozapine, lamotrigine, lithium,
and valproate); (2) participants who presented an autoimmune disease (15 individuals,
determined as the use of immunosuppressant medications in any study follow-up); (3) in-
dividuals who reported any viral infection (nine participants, determined as the use of oral
antiviral medication in any study follow-up) or parasitism (two participants, determined as
the use of oral anti-parasitic medication in any study follow-up); and (4) participants who
developed any cancer of the immune system throughout the study (16 individuals). No
individuals with health outcomes related to alterations in WBC count (severe blood cell and
bone marrow conditions, such as aplastic anemia, overactive spleen, and myelodysplastic
syndromes; congenital immune diseases, such as myelokathexis and Kostmann syndrome;
sarcoidosis; or having undergone a splenectomy) were included in the trial. This yielded
a main analytical sample of 4192 individuals. In the analyses related to the incidence of
WBC count alterations, we also excluded individuals with leukocytosis or leukopenia at
baseline or without information on WBC count in the follow-up visits. The flowchart of the
study is available in Figure 1.
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Figure 1. Study flowchart.
2.2. Dietary Intervention
Volunteers were randomly assigned to one of the three intervention arms on a 1:1:1 ra-
tio. MedDiet interventions promoted (1) the consumption of plant-based foods (such as
fruits, vegetables, legumes, and nuts) and fish; (2) the use of extra-virgin olive oil as a
main culinary fat; (3) a decrease in the intake of sugary drinks, commercial bakery goods,
sweets, pastries, and fat spreads; (4) the substitution of red/processed meats for poultry;
and (5) the consumption of foods prepared by home-made methods (such as the traditional
“sofrito”, a stir-fried sauce of tomato, garlic, onion, or leeks sautéed in olive oil). To boost
compliance and account for family needs, volunteers allocated in the MedDiet–EVOO
intervention received 1 L/week of extra-virgin olive oil and those in the MedDiet–Nuts
group were provided with 210 g/week of mixed nuts plus three monthly 1 kg packs.
Volunteers allocated to the low-fat control group were advised (1) to promote the intake
of fruits, vegetables, legumes, low-fat dairy products, lean fish, and seafood; and (2) to
decrease their consumption of vegetable oils (including olive oil), commercial bakery goods
and sweets, nuts and fried snacks, red and processed fatty meats, visible fat in meats and
soups, fatty fish, seafood canned in oil, spread fats, and sofrito. Further details of the
dietary protocol have been described [14,34,35].
As a secondary measurement of dietary exposure, we also estimated the adherence of
study participants to a MedDiet at each visit using the MedDiet adherence score. It was a
validated short screener questioning whether the volunteer followed 14 essential dietary
traits related to a MedDiet. It scored positively on the consumption of (1) olive oil (used
as main fat for cooking and seasoning earned 1 point, an intake of ≥4 tablespoons/day
earned an additional 1 point); (2) vegetables (≥2 servings/day); (3) fruit (≥3 servings/day);
(4) mixed nuts (≥3 servings/week); (5) legumes (≥3 servings/week); (6) fish/seafood (≥3
servings/week); (7) poultry and rabbit over red/processed meat (1 point, plus an additional
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1 point if the consumption of red/processed meat was <1 serving/day); (8) <1 serving per
day of butter, margarine, or cream; (9) <1 carbonated/sugar-sweetened beverage per day;
(10) <2 servings per week of non-homemade sweets/pastries; (11) wine in moderation (100
mL/day, within meals); and (12) a sofrito-based dish at least twice per week [36].
2.3. Outcomes
First, WBC count was measured in fasting plasma samples in an automated analyzer
as previously described [37]. The normal range for WBC count in male and non-pregnant
female adults is usually defined as 4.5 to 11.0 × 109 cells/L [38]. Thus, leukopenia was de-
fined as presenting ≤4.5 × 109 cells/L, and leukocytosis as ≥11 × 109 cells/L. Considering
that other studies have used stricter definitions in the particular case of leukopenia [39], we
additionally defined “severe leukopenia” as presenting ≤3.5 × 109 cells/L. We calculated
incidence and time-to-event of the onset of any of these three conditions among volunteers
without extreme WBC count at the beginning of the study. We defined “onset” as the
appearance of any of the above conditions in one of the follow-ups that lasted until the last
visit for which data is available. We considered as a valid incident case any presentation of
a WBC count alteration that persisted for at least three subsequent follow-up visits and
had no more than one “return to normal” value.
For our secondary analysis, we collected information on all-cause mortality. A clinical
event committee checked any fatal outcome up to 1 December 2010, as well as the date
of death, using the information available from follow-up study visits, yearly review of
medical records between 2011 and 2017, repeated contact with the participants, and the
national death registry [14,34].
2.4. Covariates
Trained personnel collected data on age; sex; educational level; prevalence of diabetes,
hypercholesterolemia, hypertriglyceridemia, and hypertension; body mass index; and
smoking habits [14,34]. We extracted the hemoglobin values (a key covariate in WBC-
related analyses [40]) from the same complete blood count from which the WBC count
came [37]. We estimated physical activity levels in metabolic equivalents of task-minute
per day from the Minnesota Leisure-Time Physical Activity Questionnaire validated for
the Spanish adult population [41,42]. Finally, we estimated alcohol intake (in g/day)
from a semi-quantitative 137-item food frequency questionnaire, also validated in Spanish
adults [43].
2.5. Power Analysis
The number of individuals and cases in each study group allowed us to detect as
significant (p-value <0.05, ≥80% power) hazard ratios (HR) for the comparisons between
the low-fat control diet and (1) both MedDiet interventions combined, (2) MedDiet–EVOO,
and (3) MedDiet–Nuts, respectively, of the following values: ≤0.43, 0.33, and 0.30 in
relation to leukocytosis onset; ≤0.59, 0.54, and 0.50 regarding leukopenia onset; and ≤0.32,
0.24, and 0.17 regarding severe LEUKOPENIA (Table S1). We performed these analyses
using the “powerSurvEpi” package in R Software (Vienna, Austria) [44].
2.6. Statistical Analyses
We described baseline characteristics of the volunteers using means and standard
deviation (normally distributed continuous variables), medians and interquartile range
(non-normally distributed continuous variables), and proportions (categorical variables).
We compared our study population with the subset of non-included volunteers of the
PREDIMED study by one-way analysis of variance tests for normally distributed continu-
ous variables, Kruskal–Wallis tests for non-normally distributed continuous variables, and
Pearson chi-squared tests for categorical variables.
We used three sets of Cox proportional hazards regression models where the outcomes
were the risk of developing leukocytosis, leukopenia, and severe leukopenia. Follow-up
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time was defined as the time between the date of enrollment and (1) the midpoint between
the last visit without the outcome and the first visit in which the WBC abnormality was
registered [45]; (2) 6 years of maximum follow-up time; or (3) 1 December 2010, whichever
came first. We investigated whether there were differences in the risk of presenting the
outcome in the two MedDiet intervention groups (combined and individually) relative to
the control diet. We adjusted Cox models for sex (strata variable), recruitment site (strata
variable), educational level (primary, secondary, tertiary, unavailable information; strata
variable), WBC count at baseline (continuous), age (continuous), diabetes (yes/no), hyperc-
holesterolemia (yes/no), hypertriglyceridemia (yes/no), hypertension (yes/no), smoking
habit (current/former/never smoker), hemoglobin levels (continuous), leisure-time physi-
cal activity (continuous), body mass index (continuous), alcohol consumption (continuous),
and two propensity scores that used 30 baseline variables to estimate the probability of
assignment to each of the intervention groups. We used robust variance estimators to
account for intra-cluster correlations [14] and fitted models using the “survival” package in
R Software [46]. We also depicted incident cases using Kaplan–Meier cumulative incidence
curves for study groups using inverse probability weighting with a propensity score model
of assignment to intervention or control group based on the covariates above listed.
We investigated the effects of MedDiet interventions on 6-year WBC count evolution
as a continuous variable by repeated measurement mixed models. We assessed time effects
(continuous change per year in the whole study population) and between-group changes
(difference in changes over time in MedDiet intervention groups, combined and individual,
relative to the control diet). Models included the same covariates as above and were fitted
using the “lme4” package in R Software [47].
In addition to the intention-to-treat approach, we considered adherence to the Med-
Diet as exposure. We calculated the cumulative average MedDiet adherence as the mean of
all the 14-point MedDiet adherence score values until the occurrence of the event (incident
cases) or the last study visit with available data (non-cases). We used this variable as con-
tinuous and in quartiles. Cox models were stratified and adjusted for the same covariates
as in the intention-to-treat analyses plus the PREDIMED intervention group. In addition,
we used multiple linear regressions with cubic spline models to analyze the dose-response
association between the cumulative adherence to a MedDiet and the cumulative mean of
WBC count throughout the study (calculated similarly as for MedDiet adherence score). We
set the reference cut-point at the minimum observed value (5 points out of 14). Cumulative
means of WBC count whose values departed from the average by more than two standard
deviations were considered outliers and excluded from the analyses. We performed the
previous analyses in the whole study population and stratifying volunteers in quartiles
according to WBC count at baseline (after testing whether there was a significant interac-
tion between baseline WBC count and the cumulative MedDiet adherence, by applying
a likelihood ratio test between the nested models with the interaction product-term and
without it). Models included the same covariates as for survival analyses according to
cumulative MedDiet adherence. Splines were fitted and plotted using the “gam” package
in R Software [48].
Finally, we determined whether MedDiet modified the association between WBC
count alterations at baseline and all-cause mortality. We compared the volunteers: (1)
allocated to the MedDiet interventions relative to those in the control group; and (2) with a
high cumulative MedDiet adherence (above the median) relative to those with low values
(below the median). To determine whether the interaction between MedDiet group and
WBC alterations was significant, we fitted Cox models where the outcome was all-cause
mortality and applied a likelihood ratio test between the nested models with and without
an interaction product-term of “WBC count alteration × group”.
A two-sided p-value < 0.05 was considered significant. We performed all analyses
with R Software, version 3.5.0 (Vienna, Austria) [49].
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3. Results
3.1. Study Population
Our study sub-sample were elderly adults (mean age 67 years, 58% women) with high
prevalence of cardiovascular risk factors at baseline (84% hypertension, 74% hypercholes-
terolemia, 49% obesity, 46% diabetes, 30% hypertriglyceridemia, 14% current smokers)
(Table 1). Individuals in the analytical sample were less likely to have type-2 diabetes
and more prone to present hypercholesterolemia, hypertriglyceridemia, hypertension, and
obesity than the PREDIMED participants not included in the analyses (Table S2). The
numbers of individuals considered in the analyses on the onset of leukocytosis, leukopenia,
and severe leukopenia were 3190, 2925, and 3190, respectively. Median follow-up time was
3.2 years.









Age (years), mean ± SD 67.1 ± 6.14 66.8 ± 6.08 66.9 ± 6.04 67.5 ± 6.28
Female sex, n (%) 2416 (57.6) 854 (59.3) 719 (54.1) 843 (59.2)
Diabetes, n (%) 1949 (46.5) 683 (47.5) 607 (45.7) 659 (46.2)
Hypercholesterolemia, n (%) 3103 (74.0) 1062 (73.8) 995 (74.9) 1046 (73.4)
Hypertriglyceridemia, n (%) 1269 (30.3) 437 (30.4) 402 (30.3) 430 (30.2)
Hypertension, n (%) 3512 (83.8) 1196 (83.1) 1114 (83.9) 1202 (84.4)
Smoking habit:
Never smokers, n (%) 2580 (61.5) 892 (62.0) 796 (59.9) 892 (62.6)
Current smokers, n (%) 574 (13.7) 193 (13.4) 188 (14.2) 193 (13.5)
Former smokers, n (%) 1038 (24.8) 354 (24.6) 344 (25.9) 340 (23.9)
Weight status:
Body mass index <25 kg/m2, n (%) 283 (6.75) 99 (6.88) 104 (7.83) 80 (5.61)
Overweight (25–29.9 kg/m2), n (%) 1857 (44.3) 642 (44.6) 604 (45.5) 611 (42.9)
Obesity (≥30 kg/m2), n (%) 2052 (49.0) 698 (48.5) 620 (46.7) 734 (51.5)
MedDiet adherence score, mean ± SD 8.62 ± 1.96 8.76 ± 1.99 8.70 ± 1.96 8.40 ± 1.91
Leisure-time physical activity (metabolic
equivalents of task/minute/d), median
(1st–3rd quartile)
168 (56.2–315) 176 (61.8–319) 183 (63.9–328) 150 (47.4–281)
1 MedDiet–EVOO: Mediterranean diet enriched with extra-virgin olive oil; MedDiet–Nuts: Mediterranean diet enriched with mixed nuts.
3.2. Intervention with MedDiet and Incidence of WBC Count Alterations
As seen in Table 2, both MedDiet interventions combined were associated with 46%
less risk of developing leukopenia (HR = 0.54 [95% confidence interval: 0.36; 0.80]). The
association was significant and of a similar magnitude when individual MedDiet inter-
vention groups were considered (HRMedDiet–EVOO = 0.59 [0.38; 0.93], HRMedDiet–Nuts = 0.47
[0.29; 0.78]). In addition, MedDiet interventions were also linked to lower incidence of se-
vere leukopenia (HRMedDiets combined = 0.25 [0.10; 0.60], HRMedDiet–EVOO = 0.31 [0.11; 0.85],
HRMedDiet–Nuts = 0.18 [0.055; 0.60]). No significant effects were found for leukocytosis.
Weighted Kaplan–Meier curves are available in Figure S1.
Despite the effect of MedDiet interventions on the risk of leukopenia, WBC count
increased throughout follow-ups in the whole study population (+0.026 × 109 cells/L·year
[0.003; 0.049]) but this trend was not different between study groups (Table S3).
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Table 2. Incidence of white blood cell count alterations in the study population1.






















































1 Hazard ratios were estimated by multivariable Cox proportional hazards regression models stratified by sex, recruitment site, and
educational level, and adjusted for white blood cell count, age, diabetes, hypercholesterolemia, hypertriglyceridemia, hypertension,
smoking habit, leisure-time physical activity, body mass index, hemoglobin levels, alcohol consumption (baseline values, all), and two
propensity scores that used 30 baseline variables to estimate the probability of assignment to each of the intervention groups. We used
robust standard errors to account for intra-cluster correlations. MedDiet–EVOO: Mediterranean diet enriched with extra-virgin olive oil;
MedDiet–Nuts: Mediterranean diet enriched with mixed nuts.
3.3. MedDiet Adherence and WBC Count
High cumulative MedDiet adherence was associated with lower risk of developing
leukocytosis (+1 point in cumulative adherence: HR = 0.72 [0.57; 0.92]), mainly due to
individuals with greater adherence (HRQ4 vs. Q1 = 0.29 [0.085; 0.99]; Figure 2a). We also
observed a linear association between increasing MedDiet adherence and lower risk of
leukopenia (+1 point in cumulative adherence: HR = 0.69 [0.58; 0.82]; HRQ4 vs. Q1 = 0.35
[0.17; 0.72]; Figure 2b). Finally, we detected an association between cumulative MedDiet
adherence and reduced risk of severe leukopenia, possibly non-linear due to the limited
amount of incident cases of the outcome (+1 point in cumulative adherence: HR = 0.69
[0.51; 0.95]; HRQ2 vs. Q1 = 0.18 [0.042; 0.74], HRQ3 vs. Q1 = 0.26 [0.085; 0.81], HRQ4 vs. Q1 =
0.61 [0.22; 1.68]; Figure 2c).
Figure 2. Associations of cumulative MedDiet adherence and risk of leukocytosis (a), leukopenia (b), and severe leukopenia
(c). Hazard ratios were estimated by multivariable Cox regression models stratified by sex, recruitment site, and educational
level, and adjusted for white blood cell count, age, diabetes, hypercholesterolemia, hypertriglyceridemia, hypertension,
smoking habit, leisure-time physical activity, body mass index, hemoglobin levels, alcohol consumption (baseline values,
all), and PREDIMED intervention group. We used robust standard errors to account for intra-cluster correlations.
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Cumulative MedDiet adherence was unrelated to the cumulative mean of WBC count
(−0.011 × 109 cells/L [−0.027; 0.004], p-value for linear association = 0.14; p-value for
non-linear association = 0.11). However, associations between these two parameters were
different according to baseline WBC count (p-value for the interaction between baseline
count and cumulative MedDiet adherence < 0.001). A positive relationship between
cumulative MedDiet adherence and WBC count was suggested in volunteers with low
baseline levels (first quartile); on the contrary, inverse associations were found in the third
and fourth quartile of baseline WBC count (Figure 3).
Figure 3. Associations between cumulative means of MedDiet adherence scores and white blood
cell count throughout the study stratified according to baseline levels: first (a), second (b), third
(c), and fourth quartiles (d). Dose-dependent associations between cumulative means of MedDiet
adherence scores and cumulative means of white blood cells were estimated by multiple linear
regressions with cubic spline models. Models were adjusted for white blood cell count at baseline,
age, sex, recruitment site, educational level, diabetes, hypercholesterolemia, hypertriglyceridemia,
hypertension, smoking habit, leisure-time physical activity, body mass index, hemoglobin levels,
alcohol consumption (baseline values, all), and PREDIMED intervention group.
3.4. Interaction between WBC Count-Related Alterations and MedDiet on All-Cause Mortality
Leukocytosis was not associated with all-cause mortality, modulated or not by Med-
Diet (Figure 4a). However, high adherence to a MedDiet attenuated the relationship
between leukopenia and all-cause mortality (HRbelow-median adherence = 1.80 [0.92; 3.55],
HRabove-median adherence = 0.54 [0.19; 1.54], p-interaction = 0.032; Figure 4b). Exact values of
HRs are available in Table S4.
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Figure 4. Associations of leukocytosis (a) and leukopenia (b) with all-cause mortality risk stratified by MedDiet groups.
Hazard ratios were estimated by multivariable Cox proportional hazards regression models stratified by sex, recruitment site,
and educational level, and adjusted for white blood cell count, age, diabetes, hypercholesterolemia, hypertriglyceridemia,
hypertension, smoking habit, leisure-time physical activity, body mass index, hemoglobin levels, and alcohol consumption
(at baseline). Analyses stratified according to cumulative MedDiet adherence were further adjusted for PREDIMED
intervention group. We used robust standard errors to account for intra-cluster correlations.
4. Discussion
Our results show that a MedDiet intervention was associated with a lower risk of
developing mild and severe leukopenia in middle-aged and older adults at high cardiovas-
cular risk. In addition, high adherence to a MedDiet—regardless of the intervention—was
associated with decreased incidence of any WBC count alteration and attenuated all-cause
mortality risk linked to leukopenia.
Our main finding is the protective effect of MedDiet on onset of leukopenia (both
MedDiet interventions combined decreased the risk by 46%), reducing, in particular, the
incidence of severe leukopenias (by 75%). In addition, high adherence to the MedDiet
attenuated mortality risk in individuals with low WBC count. Leukopenia is a well-known
indicator of frailty, particularly when one is suffering an infectious disease. Its presence
has been shown to be highly prevalent in hospitalized patients with confirmed COVID-19
infection [50], is associated with increased severity of respiratory disease by Klebsiella
pneumoniae [28], Staphylococcus aureus [29], and Mycobacterium tuberculosis [51], and is
a predictor of mortality in patients with yellow fever [27] and after acute care surgery [52].
Low WBC counts are known to appear in nutritional deficits, chronic use of certain med-
ications, and clinical outcomes such as autoimmune diseases, cancers of the immune
system, infections, and bone marrow, blood, and spleen disorders [32,33]. Thus, the as-
sociation of the MedDiet with a lower incidence of leukopenia and the attenuation of
the leukopenia-related mortality risk suggests a beneficial impact of this dietary pattern
in immune function due to the improvement in the nutritional status after the MedDiet
interventions [32,33].
High adherence to the MedDiet was additionally related to a decreased risk of devel-
oping leukocytosis. Previous cross-sectional analyses [53,54] and a short-term, small-scale
intervention study with a MedDiet–inspired dietary pattern [55] have reported similar
results. Adherence to the Dietary Approaches to Stop Hypertension eating plan and lower
scores in the Dietary Inflammatory Index (increments in diet quality) were associated with
reduced WBC levels [56,57], and a short-term, small-scale intervention based on a vegan
diet (plant-rich as the MedDiet) has also been shown to decrease WBC count [58]. High
WBC count is a marker of low-grade inflammation [30,59] and has been associated with a
greater incidence of inflammation-related disease in the general population and in individ-
uals at high cardiovascular risk [31]. Thus, the anti-inflammatory capacity of the MedDiet
(which has already been associated with decreased levels of pro-inflammatory cytokines
such as C-reactive protein, interleukin-6, tumor necrosis factor α, macrophage chemotactic
protein-1, and soluble intercellular adhesion molecule-1 in the PREDIMED study [17,18])
may contribute to explaining this beneficial effect on WBC count. Several MedDiet bioactive
compounds act synergistically to promote this anti-inflammatory effect. First, antioxidants
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(present in extra-virgin olive oil, nuts, fruits, vegetables, and legumes) neutralize reactive
species of oxygen and nitrogen. This, in turn, decreases the excessive activation of nuclear
factor kappa beta, the main cellular regulator of inflammatory responses, through the
regulation of phosphoinositol-3-kinase-related pathways [60]. Some particular MedDiet
antioxidants such as flavonoids are able to directly modulate the disproportionate promo-
tion of phosphoinositol-3-kinase-related pathways [61]. Second, monounsaturated (in olive
oil) and polyunsaturated fatty acids (in nuts, fish, and seafood) contribute to reducing low-
grade inflammation through their capacity to activate peroxisome-proliferator activated
receptors [62] and bind fatty acid receptors in immune cells [63]. In addition, omega-3
polyunsaturated fatty acids can be transformed into anti-inflammatory eicosanoids such
as 3-series prostaglandins and thromboxanes and 5-series leukotrienes [64]. Third, minor
polar lipids present in several foods in the MedDiet (such as the glycerophospholipids,
glycolipids, and betaine-related lipids in extra-virgin olive oil) are able to contribute to the
anti-inflammatory potential of this dietary pattern due to their capacity to counteract the
pro-inflammatory signaling pathways of platelet-activating factor [65,66]. Finally, short-
chain fatty acids (such as butyric, propionic, and acetic acids, derived from the intestinal
fermentation of dietary fiber by probiotic bacteria) and some phenolic compounds are
able to induce the activation of AMP-activated protein kinase [67,68], a cellular metabolic
regulator capable of counteracting an exaggerated inflammatory response through its
ability to induce several anti-inflammatory responses [69].
Our study presents some limitations. First, WBC count alterations were not a predeter-
mined endpoint in the PREDIMED trial and, therefore, these analyses should be considered
as exploratory. Second, our cohort of participants, studied between 2003 and 2009, could
possibly be outdated to argue the significance of our findings, and therefore our conclu-
sions should be validated in a more recent population to confirm their robustness. Third,
WBC counts fluctuate over time (due to infections, daily life activities, and the individuals’
mood) and WBC count alterations had a low incidence rate in our population. Therefore,
our findings should be interpreted with caution. Fourth, WBC counts were measured
in different recruiting centers, which could have increased data variability. However, all
analyses were stratified by recruiting site and adjusted for baseline WBC count values, and
the inter-center coefficient of variability for the mean count value obtained for each site
throughout the whole study is low (3.70%). Fifth, generalizability of our results to other
populations than middle-aged and older adults at high cardiovascular risk is limited. Sixth,
we were only capable of reporting moderate effects on some of the study outcomes, consid-
ering that MedDiet interventions were based on modest real-life dietary modifications and
that the control diet was already a healthy, low-fat dietary pattern. Finally, self-reported
information on dietary adherence and leisure-time physical activity is subjected to bias and
the risk of residual confounding.
5. Conclusions
Our findings indicate that following a MedDiet reduced the risk of developing leukope-
nia in middle-aged and older adults at high cardiovascular risk. Additionally, high MedDiet
adherence was associated with a decreased incidence of any WBC count alteration and
attenuated all-cause mortality risk linked to leukopenia. Our findings suggest that the
MedDiet could be a recommended eating plan in middle-aged and older adults with car-
diovascular comorbidities in which leukopenia may lead to serious health consequences.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/foods10061268/s1, Figure S1: Weighted Kaplan–Meier estimates of the cumulative incidence
of leukocytosis (a), leukopenia (b), and severe leukopenia (c) in intervention groups; Table S1: Power
analyses for all study determinations; Table S2: Comparison of study population with non-included
PREDIMED participants; Table S3: Evolution over time of white blood cell count in the PREDIMED
study groups; Table S4: Associations of white blood cell count alterations at baseline with the risk of
all-cause mortality stratified by intervention group and cumulative adherence to the Mediterranean
diet.
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